Clinical trial
Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
NCT03198026 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 20, 2018
- Completion date
- February 20, 2032
- Enrollment
- 29 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ann abor stage iii b-cell non-hodgkin lymphoma, ann arbor stage ii extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, ann arbor stage ii follicular lymphoma, ann arbor stage ii nodal marginal zone lymphoma, ann arbor stage iii extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, ann arbor stage iii follicular lymphoma, ann arbor stage iii nodal marginal zone lymphoma, ann arbor stage iv b-cell non-hodgkin lymphoma, ann arbor stage iv extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, ann arbor stage iv follicular lymphoma, ann arbor stage iv nodal marginal zone lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, indolent non-hodgkin lymphoma, non-hodgkin's lymphoma, stage ii splenic marginal zone lymphoma, stage iii splenic marginal zone lymphoma, stage iv splenic marginal zone lymphoma